Navigation Links
Research consortium at CHLA receives $410,000 to study leukemia and lymphoma
Date:7/20/2010

LOS ANGELES (July 19, 2010) J. Eric Bubbers, PhD, of the Saban Research Institute at Childrens Hospital Los Angeles, has received a $410,000 grant from Phase One Foundation. The award will fund a "first in childhood leukemia" multi-site study in children with relapsed or refractory acute lymphocytic leukemia (ALL) or acute myelogenous leukemia (AML). Dr. Bubbers is the administrative director of Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL), an academic research consortium consisting of 33 member institutions in four countries.

"Both ALL and AML are cancers of the blood and bone marrow, with ALL being the most common cancer occurring in children," explains Dr Bubbers. "These diseases begin when a single cell changes from a normal cell to a cancer cell. Patients receive treatment chemotherapy and/or radiation with the hope of achieving remission. But sometimes that doesn't happen, or the remission doesn't last."

A child is in remission when he or she is not showing any signs or symptoms of disease. But sometimes the cancer cells return. This condition is called relapse. Other patients undergo treatment but not all the cancer cells are gone from their body. In this case, the patient has refractory disease. When a child has relapsed or refractory disease, different treatments may be required.

The TACL consortium is studying a new alternative treatment for these patients. Gene-targeted therapy, a type of personalized medicine, is based on the specific type of chromosomal changes occurring in a patient's cells. Certain genetic mutations, those of FLT3 and c-Kit, are associated with a particularly poor prognosis. This multi-center study will use a new drug that has been expressly optimized to inhibit FLT3 and c-Kit and has been effective in treating adults with these diseases. The goal of the phase I study is to determine a safe and biologically-active dose in young patients.


'/>"/>

Contact: Ellin Kavanagh
ekavanagh@chla.usc.edu
323-361-8505
Children's Hospital Los Angeles
Source:Eurekalert

Page: 1

Related medicine news :

1. Concordia researcher leads study that finds kids reduce physical activity for heart patients
2. U of Us Janice Morse inducted into International Nurse Researcher Hall of Fame
3. Researchers Use Ecstasy to Treat PTSD
4. Licensed Florida Tech research makes lab work easier
5. New research finds major activation themes in denture-stomatitis
6. UC San Diego researchers find cause of metabolic disease -- and possible cure
7. Researchers cut years from drug development with nanoscopic bead technology
8. New research explores relief for xerostomia cancer patients
9. 5 awarded ASTRO research grants
10. Lu receives grant from Research to Prevent Blindness organization
11. NIH expands food allergy research program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... CARTERSVILLE, Georgia (PRWEB) , ... March 28, 2017 ... ... analyst to its award-winning team. Ruel Williamson brings his extensive knowledge of appraisals, ... been a leader in the real estate valuation industry for more than 40 ...
(Date:3/28/2017)... ... March 29, 2017 , ... Dr. Isabella Wentz, PharmD, FASCP, one ... video series titled The Thyroid Secret. Dr. Wentz talked about journey and research recently ... fact that medication IS NOT the only solution to deal with thyroid disease. ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... and by physicians, announced today the launch of a free, public-facing tool for ... Cost Analyzer (VCA) was developed to provide comparative information to patients, providers, insurers ...
(Date:3/28/2017)... , ... March 28, 2017 , ... Usually, the impending ... daily wardrobe. However, for those self-conscious about a double chin, this means more anxiety ... ideal solution. , “For most people, a double chin is undesirable,” Dr. Goldman ...
(Date:3/28/2017)... ... March 28, 2017 , ... Qualidigm , the ... headquarters to a new, more expansive office space in order to accommodate its ... a distressed office building in Wethersfield, Conn. located at 936 Silas Deane Highway ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... REDWOOD CITY, Calif. , March 28, 2017 ... pharmaceutical company focused on the development and commercialization ... acute pain, announced that the European Medicines Agency ... (sufentanil sublingual tablet, 30 mcg) Marketing Authorisation Application ... review of the MAA is underway. The MAA ...
(Date:3/28/2017)... , March 28, 2017  Medeon Biodesign, Inc., ... company, is pleased to announce that the Company ... of Panther Orthopedics, Inc., a San ... fixation solutions for orthopedic extremity applications.  ... expand rapidly, primarily due to procedure volume growth, ...
(Date:3/27/2017)... 2017 Therapix Biosciences Ltd. ... in the development of cannabinoid-based drugs, today announced ... the United States of 2,000,000 ... ordinary shares of the Company, at a price ... granted the underwriters a 45-day over-allotment option to ...
Breaking Medicine Technology: